The Japanese drugmaker’s review compared data for 72 patients with early Alzheimer’s given Leqembi by subcutaneous injection to prior pivotal trial results from 898 patients who received the drug by infusion. The intravenous (IV) form of Leqembi won U.S. approval based on that larger 18-month study showing the drug, which works by removing sticky clumps of beta amyloid from the brain, slowed cognitive decline by 27 per cent for people with early Alzheimer’s disease., The Japanese drugmaker’s review compared data for 72 patients with early Alzheimer’s given Leqembi by subcutaneous injection to prior pivotal trial results from 898 patients who received the drug by infusion. The intravenous (IV) form of Leqembi won U.S. approval based on that larger 18-month study showing the drug, which works by removing sticky clumps of beta amyloid from the brain, slowed cognitive decline by 27 per cent for people with early Alzheimer’s disease., , Read More
AAS Yoga
Go for Euphoria – Illness to Wellness the Natural Way